Vir Biotechnology develops antibody-based and other biologic therapies aimed at serious infectious diseases and related conditions, using proprietary discovery platforms that incorporate computational and AI-assisted design. The company has advanced programs historically spanning viral infections such as hepatitis and respiratory disease, often via partnerships with larger pharma. Its customers in the commercial sense are future patients and payers; near-term value is driven by the clinical pipeline rather than large product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1 | — | -111 | — |
| Q3 2025 | -0.1 | — | -163.1 | — |
| Q4 2025 | 63.8 | — | -42.9 | — |
| Q1 2026 | -0 | — | -125.7 | — |
| Q2 2026 | 238.9 | 23,075.1% | 80.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Braveheart Bio, Inc. (BRVE), Happen, Inc. (HAPN), Personalis, Inc. (PSNL), Progress Software Corporation (PRGS), FirstSun Capital Bancorp (FSUN), Neutron Holdings, Inc. (LIME)